Cravath’s New York Office Moves to Two Manhattan West
David R. Marriott focuses his practice on litigating complex disputes, regularly handling his clients’ most critical cases. The American Lawyer has named him a “Litigator of the Year” and repeatedly recognized him as “Litigator of the Week.” Among other accolades, he was named a “Litigation Trailblazer” by The National Law Journal and “Trial Lawyer of the Year” by Benchmark Litigation. He is a fellow of the American College of Trial Lawyers and the International Academy of Trial Lawyers.
Praised as “the go-to lawyer for high-stakes litigation” and “one of the best trial attorneys in the US,” Mr. Marriott has tried numerous state and federal cases, handled more than two dozen appeals and been involved in various forms of alternative dispute resolution. (IAM Patent 1000) Named a “Competition/Antitrust MVP” by Law360, he has taken a leading role in precedent-setting antitrust disputes, in addition to his significant experience in intellectual property, general commercial and securities matters. The Legal 500 US has repeatedly recognized Mr. Marriott as a “Leading Trial Lawyer,” noting his “versatility and trial experience” and regular representation of some of “the firm’s most high profile clients.”
Mr. Marriott’s clients have included Alcon Laboratories, AT&T, Avon Products, Bank of America, Bausch Health Companies, Bristol‑Myers Squibb, Colgate‑Palmolive, Corteva, CSX Corporation, Delta Air Lines, Eli Lilly, Forward Air, Frontier Communications, IBM, Illumina, Louis Dreyfus, Olin Corporation, NCR, Novartis, Qualcomm, Tesla, Truist Bank, Unilever, Viatris, the Massachusetts Institute of Technology and the President and Fellows of Harvard College.
Some of Mr. Marriott’s notable representations include:
Antitrust
Representing Illumina in an administrative challenge brought by the Federal Trade Commission (FTC) concerning Illumina’s $8 billion acquisition of GRAIL, a healthcare company developing a cancer screening test for 50 cancer types. In September 2022, Mr. Marriott obtained an unprecedented trial win, in which the FTC’s Chief Administrative Law Judge ruled in favor of Illumina and rejected the FTC’s merger challenge. In connection with this victory, he was recognized as The Am Law Litigation Daily’s “Litigator of the Week.”
Representing Corteva in antitrust litigation filed by the FTC and 12 state attorneys general challenging certain of its rebate pricing programs as anticompetitive. Plaintiffs assert violations of the FTC Act, Clayton Act and Sherman Act, as well as various state competition and consumer protection laws. Mr. Marriott also represents Corteva in related putative class action litigation, centralized in North Carolina federal court, filed in the wake of the FTC’s complaint.
Intellectual Property
Securities
Additional Trial Experience
Select Additional Representations
Represented Unilever PLC and its affiliates, Unilever IP Holdings B.V. and Conopco, Inc., in an action brought by its wholly owned subsidiary Ben & Jerry’s in New York federal court challenging the sale of Ben & Jerry’s Israeli business interests.
Represented the late publisher Katharine Graham (owner of The Washington Post) concerning the constitutionality of a D.C. statute that imposed a fiduciary income tax on trusts.
Mr. Marriott is the editor of New York Business Litigation (NYLJ 2013‑2018, 2020, 2022, 2024) and a contributing author and editor of Winning at Trial (ALM 2014). He has written numerous articles related to trial practice, complex litigation and ethics for New York Law Journal and the Practising Law Institute (“PLI”). Mr. Marriott also chairs PLI’s “Trial by Jury” conference and has been a repeat moderator of other PLI conferences, such as “Bet the Company Litigation.” For several years, he chaired the New York City Bar’s annual “Institute for Corporate Counsel.”
Mr. Marriott is an Adjunct Professor at New York University School of Law and a Lecturer in Law at Columbia University School of Law. He teaches antitrust, intellectual property and trial practice.
Mr. Marriott has been recognized by numerous publications, including Chambers USA in its antitrust and trial lawyer rankings. The Legal 500 US has recommended his work in antitrust, general commercial and patent litigation, including naming him a “Leading Lawyer” for his general commercial work. Among other recognitions, Benchmark Litigation has named Mr. Marriott one of the “Top 100 Trial Lawyers in America,” a “National Star” in general commercial litigation and a “Litigation Star” in the New York area. Lawdragon has named him a nationwide “Legend” and included him in its “500 Leading Lawyers in America,” “500 Leading Global Litigators” and “500 Leading Litigators in America” lists. In addition, he was named to Forbes’s 2024 list of “America’s Top 200 Lawyers” and recognized by the Daily Journal as a 2024 “Leading Commercial Litigator.” Mr. Marriott has been recognized by several other legal rankings publications, including The Best Lawyers in America, IAM Patent, Leaders League, LMG Life Sciences and Super Lawyers.
Mr. Marriott is admitted on the federal level, before the U.S. Supreme Court; the U.S. Courts of Appeals for the Federal, First, Second, Third, Fourth, Sixth, Ninth, Tenth and Eleventh Circuits; and the U.S. District Courts for the District of Utah, the Eastern District of New York, the Eastern District of Michigan, the Northern District of California, the Southern District of New York and the Western District of Michigan.
Mr. Marriott received a B.A. magna cum laude from Brigham Young University in 1991 and a J.D. from New York University School of Law in 1994. After graduating, he served as law clerk to Hon. Eugene F. Lynch of the U.S. District Court for the Northern District of California and to Hon. Albert J. Engel of the U.S. Court of Appeals for the Sixth Circuit.
Mr. Marriott joined Cravath in 1996 and was elected a partner in 2002.
Mr. Marriott’s clients have included Alcon Laboratories, AT&T, Avon Products, Bank of America, Bausch Health Companies, Bristol‑Myers Squibb, Colgate‑Palmolive, Corteva, CSX Corporation, Delta Air Lines, Eli Lilly, Forward Air, Frontier Communications, IBM, Illumina, Louis Dreyfus, Olin Corporation, NCR, Novartis, Qualcomm, Tesla, Truist Bank, Unilever, Viatris, the Massachusetts Institute of Technology and the President and Fellows of Harvard College.
Some of Mr. Marriott’s notable representations include:
Antitrust
Representing Illumina in an administrative challenge brought by the Federal Trade Commission (FTC) concerning Illumina’s $8 billion acquisition of GRAIL, a healthcare company developing a cancer screening test for 50 cancer types. In September 2022, Mr. Marriott obtained an unprecedented trial win, in which the FTC’s Chief Administrative Law Judge ruled in favor of Illumina and rejected the FTC’s merger challenge. In connection with this victory, he was recognized as The Am Law Litigation Daily’s “Litigator of the Week.”
Representing Corteva in antitrust litigation filed by the FTC and 12 state attorneys general challenging certain of its rebate pricing programs as anticompetitive. Plaintiffs assert violations of the FTC Act, Clayton Act and Sherman Act, as well as various state competition and consumer protection laws. Mr. Marriott also represents Corteva in related putative class action litigation, centralized in North Carolina federal court, filed in the wake of the FTC’s complaint.
Intellectual Property
Securities
Additional Trial Experience
Select Additional Representations
Represented Unilever PLC and its affiliates, Unilever IP Holdings B.V. and Conopco, Inc., in an action brought by its wholly owned subsidiary Ben & Jerry’s in New York federal court challenging the sale of Ben & Jerry’s Israeli business interests.
Represented the late publisher Katharine Graham (owner of The Washington Post) concerning the constitutionality of a D.C. statute that imposed a fiduciary income tax on trusts.
Mr. Marriott is the editor of New York Business Litigation (NYLJ 2013‑2018, 2020, 2022, 2024) and a contributing author and editor of Winning at Trial (ALM 2014). He has written numerous articles related to trial practice, complex litigation and ethics for New York Law Journal and the Practising Law Institute (“PLI”). Mr. Marriott also chairs PLI’s “Trial by Jury” conference and has been a repeat moderator of other PLI conferences, such as “Bet the Company Litigation.” For several years, he chaired the New York City Bar’s annual “Institute for Corporate Counsel.”
Mr. Marriott is an Adjunct Professor at New York University School of Law and a Lecturer in Law at Columbia University School of Law. He teaches antitrust, intellectual property and trial practice.
Mr. Marriott has been recognized by numerous publications, including Chambers USA in its antitrust and trial lawyer rankings. The Legal 500 US has recommended his work in antitrust, general commercial and patent litigation, including naming him a “Leading Lawyer” for his general commercial work. Among other recognitions, Benchmark Litigation has named Mr. Marriott one of the “Top 100 Trial Lawyers in America,” a “National Star” in general commercial litigation and a “Litigation Star” in the New York area. Lawdragon has named him a nationwide “Legend” and included him in its “500 Leading Lawyers in America,” “500 Leading Global Litigators” and “500 Leading Litigators in America” lists. In addition, he was named to Forbes’s 2024 list of “America’s Top 200 Lawyers” and recognized by the Daily Journal as a 2024 “Leading Commercial Litigator.” Mr. Marriott has been recognized by several other legal rankings publications, including The Best Lawyers in America, IAM Patent, Leaders League, LMG Life Sciences and Super Lawyers.
Mr. Marriott is admitted on the federal level, before the U.S. Supreme Court; the U.S. Courts of Appeals for the Federal, First, Second, Third, Fourth, Sixth, Ninth, Tenth and Eleventh Circuits; and the U.S. District Courts for the District of Utah, the Eastern District of New York, the Eastern District of Michigan, the Northern District of California, the Southern District of New York and the Western District of Michigan.
Mr. Marriott received a B.A. magna cum laude from Brigham Young University in 1991 and a J.D. from New York University School of Law in 1994. After graduating, he served as law clerk to Hon. Eugene F. Lynch of the U.S. District Court for the Northern District of California and to Hon. Albert J. Engel of the U.S. Court of Appeals for the Sixth Circuit.
Mr. Marriott joined Cravath in 1996 and was elected a partner in 2002.
American Bar Association
American Bar Foundation
ICC National Arbitration Committee (U.S. Council for International Business)
International Academy of Trial Lawyers
International Bar Association
New York City Bar Association
New York State Bar Association
The American Lawyer
Benchmark Litigation
Top 100 Trial Lawyers in America (2024)
General Commercial Star - National (2024-2017)
Litigation Star - New York (2024-2017)
Future Star (2016, 2015)
Best Lawyers in America
Chambers USA
Euromoney Legal Media Group
Forbes
Intellectual Asset Management
Law360
Lawdragon
Leaders League Innovation - Technology & Intellectual Property Report
Leaders League Litigation & International Arbitration Report
The Legal 500 US
National Law Journal
Super Lawyers - New York
Who's Who Legal
Deals & Cases
April 29, 2024
On Monday, April 15, 2024, the U.S. Court of Appeals for the Second Circuit affirmed the U.S. District Court for the Southern District of New York’s granting of summary judgment in favor of Cravath client Mylan in a securities class action related to Mylan’s marketing, pricing and classification of EpiPen as well as alleged conduct concerning generic drug price fixing and market allocation.
Deals & Cases
January 29, 2024
On January 25, 2024, the U.S. District Court for the Southern District of New York entered judgments against appropriation artist Richard Prince and his co‑defendants Laurence Gagosian, Gagosian Gallery and Blum & Poe gallery.
Deals & Cases
September 11, 2023
Cravath represented Amgen, one of the world’s largest biopharmaceutical companies, in successfully defending against a Federal Trade Commission (“FTC”) challenge to Amgen’s pending $27.8 billion acquisition of Horizon Therapeutics (“Horizon”)—securing a consent order on September 1, 2023 that The Wall Street Journal described as “a rare instance” of the FTC “throwing in the towel on litigation.”
Deals & Cases
July 14, 2023
On July 13, 2023, a three judge panel for the U.S. Court of Appeals for the Third Circuit ruled in favor of Cravath clients Louis Dreyfus Company LLC (“LDC”) and Imperial Sugar Company (“Imperial Sugar”) and unanimously affirmed an earlier decision by the U.S. District Court for the District of Delaware denying U.S. Department of Justice’s (“DOJ”) request for an injunction to block LDC’s sale of the assets and business of Imperial Sugar to U.S. Sugar.
Deals & Cases
May 19, 2023
On May 11, 2023, the U.S. District Court for the Southern District of New York denied summary judgment to appropriation artist Richard Prince and his associated galleries in two copyright infringement cases brought by Cravath clients, the photographers Donald Graham and Eric McNatt, regarding works from Prince’s “New Portraits” series.
Accolades
June 27, 2024
On June 25, 2024, Cravath was honored for the second consecutive year with the Gold Award as “Best US Law Firm” at the 2024 Leaders League Alliance Summit: Law & Innovation, which was held in Miami. The award was accepted by partner David R. Marriott on the Firm’s behalf. Winners were selected by more than 80 jury members “through an extremely rigorous judging process” based on nominees’ “experience and market knowledge.” The information on which Cravath’s selection was based included its representation of global companies on large and complex M&A transactions, antitrust litigation and investigations matters, as well as its innovative use of new legal technology tools.
Accolades
June 13, 2024
The IAM Patent 1000 2024, which recognizes the firms and individuals “deemed outstanding in the pivotal area of patent law,” ranked Cravath in the top tier for New York across Litigation and Transactions. In addition, Cravath partners Keith R. Hummel, David J. Kappos, David R. Marriott, Sasha Rosenthal‑Larrea and Sharonmoyee Goswami were recognized for their “outstanding service” and representation of clients on litigation and transactional matters including Johnson & Johnson in its $16.6 billion acquisition of Abiomed; Abiomed in its victory before the U.S. Patent Trial and Appeal Board; and Truist Bank in patent infringement litigation brought by United Services Automobile Association.
Accolades
March 28, 2024
On March 26, 2024, Cravath partner David R. Marriott was named to Forbes’s 2024 list of “America’s Top 200 Lawyers.” The inaugural list recognized “the finest practitioners in the profession—lawyers with stellar track records in their specialties, those who have broken barriers to emerge as leaders in their fields, and attorneys most respected by peers and clients.” Dave’s accompanying profile highlighted his experience as a “courtroom heavyweight” and his representation of clients including AT&T, Avon Products, Bank of America, Bristol‑Myers Squibb, Colgate‑Palmolive and Delta Airlines. In particular, the publication noted Dave’s achievement of “setting precedent in antitrust and intellectual property law.”
Accolades
March 14, 2024
On March 13, 2024, Benchmark Litigation honored Cravath partner David R. Marriott as its “Trial Lawyer of the Year” at the publication’s twelfth annual U.S. Awards, which were held in New York City. The awards recognize “the country’s most distinguished litigators and their firms for their exemplary work over the past twelve months.”
Activities & Publications
February 08, 2024
On February 5, 2024, The Am Law Litigation Daily interviewed Cravath partner David R. Marriot in connection with his representation of photographers Donald Graham and Eric McNatt in winning judgments against appropriation artist Richard Prince and his co defendants Laurence Gagosian, Gagosian Gallery and Blum & Poe gallery, in a case at the intersection of art, technology and copyright law.
David R. Marriott focuses his practice on litigating complex disputes, regularly handling his clients’ most critical cases. The American Lawyer has named him a “Litigator of the Year” and repeatedly recognized him as “Litigator of the Week.” Among other accolades, he was named a “Litigation Trailblazer” by The National Law Journal and “Trial Lawyer of the Year” by Benchmark Litigation. He is a fellow of the American College of Trial Lawyers and the International Academy of Trial Lawyers.
Praised as “the go-to lawyer for high-stakes litigation” and “one of the best trial attorneys in the US,” Mr. Marriott has tried numerous state and federal cases, handled more than two dozen appeals and been involved in various forms of alternative dispute resolution. (IAM Patent 1000) Named a “Competition/Antitrust MVP” by Law360, he has taken a leading role in precedent-setting antitrust disputes, in addition to his significant experience in intellectual property, general commercial and securities matters. The Legal 500 US has repeatedly recognized Mr. Marriott as a “Leading Trial Lawyer,” noting his “versatility and trial experience” and regular representation of some of “the firm’s most high profile clients.”
Mr. Marriott’s clients have included Alcon Laboratories, AT&T, Avon Products, Bank of America, Bausch Health Companies, Bristol‑Myers Squibb, Colgate‑Palmolive, Corteva, CSX Corporation, Delta Air Lines, Eli Lilly, Forward Air, Frontier Communications, IBM, Illumina, Louis Dreyfus, Olin Corporation, NCR, Novartis, Qualcomm, Tesla, Truist Bank, Unilever, Viatris, the Massachusetts Institute of Technology and the President and Fellows of Harvard College.
Some of Mr. Marriott’s notable representations include:
Antitrust
Representing Illumina in an administrative challenge brought by the Federal Trade Commission (FTC) concerning Illumina’s $8 billion acquisition of GRAIL, a healthcare company developing a cancer screening test for 50 cancer types. In September 2022, Mr. Marriott obtained an unprecedented trial win, in which the FTC’s Chief Administrative Law Judge ruled in favor of Illumina and rejected the FTC’s merger challenge. In connection with this victory, he was recognized as The Am Law Litigation Daily’s “Litigator of the Week.”
Representing Corteva in antitrust litigation filed by the FTC and 12 state attorneys general challenging certain of its rebate pricing programs as anticompetitive. Plaintiffs assert violations of the FTC Act, Clayton Act and Sherman Act, as well as various state competition and consumer protection laws. Mr. Marriott also represents Corteva in related putative class action litigation, centralized in North Carolina federal court, filed in the wake of the FTC’s complaint.
Intellectual Property
Securities
Additional Trial Experience
Select Additional Representations
Represented Unilever PLC and its affiliates, Unilever IP Holdings B.V. and Conopco, Inc., in an action brought by its wholly owned subsidiary Ben & Jerry’s in New York federal court challenging the sale of Ben & Jerry’s Israeli business interests.
Represented the late publisher Katharine Graham (owner of The Washington Post) concerning the constitutionality of a D.C. statute that imposed a fiduciary income tax on trusts.
Mr. Marriott is the editor of New York Business Litigation (NYLJ 2013‑2018, 2020, 2022, 2024) and a contributing author and editor of Winning at Trial (ALM 2014). He has written numerous articles related to trial practice, complex litigation and ethics for New York Law Journal and the Practising Law Institute (“PLI”). Mr. Marriott also chairs PLI’s “Trial by Jury” conference and has been a repeat moderator of other PLI conferences, such as “Bet the Company Litigation.” For several years, he chaired the New York City Bar’s annual “Institute for Corporate Counsel.”
Mr. Marriott is an Adjunct Professor at New York University School of Law and a Lecturer in Law at Columbia University School of Law. He teaches antitrust, intellectual property and trial practice.
Mr. Marriott has been recognized by numerous publications, including Chambers USA in its antitrust and trial lawyer rankings. The Legal 500 US has recommended his work in antitrust, general commercial and patent litigation, including naming him a “Leading Lawyer” for his general commercial work. Among other recognitions, Benchmark Litigation has named Mr. Marriott one of the “Top 100 Trial Lawyers in America,” a “National Star” in general commercial litigation and a “Litigation Star” in the New York area. Lawdragon has named him a nationwide “Legend” and included him in its “500 Leading Lawyers in America,” “500 Leading Global Litigators” and “500 Leading Litigators in America” lists. In addition, he was named to Forbes’s 2024 list of “America’s Top 200 Lawyers” and recognized by the Daily Journal as a 2024 “Leading Commercial Litigator.” Mr. Marriott has been recognized by several other legal rankings publications, including The Best Lawyers in America, IAM Patent, Leaders League, LMG Life Sciences and Super Lawyers.
Mr. Marriott is admitted on the federal level, before the U.S. Supreme Court; the U.S. Courts of Appeals for the Federal, First, Second, Third, Fourth, Sixth, Ninth, Tenth and Eleventh Circuits; and the U.S. District Courts for the District of Utah, the Eastern District of New York, the Eastern District of Michigan, the Northern District of California, the Southern District of New York and the Western District of Michigan.
Mr. Marriott received a B.A. magna cum laude from Brigham Young University in 1991 and a J.D. from New York University School of Law in 1994. After graduating, he served as law clerk to Hon. Eugene F. Lynch of the U.S. District Court for the Northern District of California and to Hon. Albert J. Engel of the U.S. Court of Appeals for the Sixth Circuit.
Mr. Marriott joined Cravath in 1996 and was elected a partner in 2002.
Mr. Marriott’s clients have included Alcon Laboratories, AT&T, Avon Products, Bank of America, Bausch Health Companies, Bristol‑Myers Squibb, Colgate‑Palmolive, Corteva, CSX Corporation, Delta Air Lines, Eli Lilly, Forward Air, Frontier Communications, IBM, Illumina, Louis Dreyfus, Olin Corporation, NCR, Novartis, Qualcomm, Tesla, Truist Bank, Unilever, Viatris, the Massachusetts Institute of Technology and the President and Fellows of Harvard College.
Some of Mr. Marriott’s notable representations include:
Antitrust
Representing Illumina in an administrative challenge brought by the Federal Trade Commission (FTC) concerning Illumina’s $8 billion acquisition of GRAIL, a healthcare company developing a cancer screening test for 50 cancer types. In September 2022, Mr. Marriott obtained an unprecedented trial win, in which the FTC’s Chief Administrative Law Judge ruled in favor of Illumina and rejected the FTC’s merger challenge. In connection with this victory, he was recognized as The Am Law Litigation Daily’s “Litigator of the Week.”
Representing Corteva in antitrust litigation filed by the FTC and 12 state attorneys general challenging certain of its rebate pricing programs as anticompetitive. Plaintiffs assert violations of the FTC Act, Clayton Act and Sherman Act, as well as various state competition and consumer protection laws. Mr. Marriott also represents Corteva in related putative class action litigation, centralized in North Carolina federal court, filed in the wake of the FTC’s complaint.
Intellectual Property
Securities
Additional Trial Experience
Select Additional Representations
Represented Unilever PLC and its affiliates, Unilever IP Holdings B.V. and Conopco, Inc., in an action brought by its wholly owned subsidiary Ben & Jerry’s in New York federal court challenging the sale of Ben & Jerry’s Israeli business interests.
Represented the late publisher Katharine Graham (owner of The Washington Post) concerning the constitutionality of a D.C. statute that imposed a fiduciary income tax on trusts.
Mr. Marriott is the editor of New York Business Litigation (NYLJ 2013‑2018, 2020, 2022, 2024) and a contributing author and editor of Winning at Trial (ALM 2014). He has written numerous articles related to trial practice, complex litigation and ethics for New York Law Journal and the Practising Law Institute (“PLI”). Mr. Marriott also chairs PLI’s “Trial by Jury” conference and has been a repeat moderator of other PLI conferences, such as “Bet the Company Litigation.” For several years, he chaired the New York City Bar’s annual “Institute for Corporate Counsel.”
Mr. Marriott is an Adjunct Professor at New York University School of Law and a Lecturer in Law at Columbia University School of Law. He teaches antitrust, intellectual property and trial practice.
Mr. Marriott has been recognized by numerous publications, including Chambers USA in its antitrust and trial lawyer rankings. The Legal 500 US has recommended his work in antitrust, general commercial and patent litigation, including naming him a “Leading Lawyer” for his general commercial work. Among other recognitions, Benchmark Litigation has named Mr. Marriott one of the “Top 100 Trial Lawyers in America,” a “National Star” in general commercial litigation and a “Litigation Star” in the New York area. Lawdragon has named him a nationwide “Legend” and included him in its “500 Leading Lawyers in America,” “500 Leading Global Litigators” and “500 Leading Litigators in America” lists. In addition, he was named to Forbes’s 2024 list of “America’s Top 200 Lawyers” and recognized by the Daily Journal as a 2024 “Leading Commercial Litigator.” Mr. Marriott has been recognized by several other legal rankings publications, including The Best Lawyers in America, IAM Patent, Leaders League, LMG Life Sciences and Super Lawyers.
Mr. Marriott is admitted on the federal level, before the U.S. Supreme Court; the U.S. Courts of Appeals for the Federal, First, Second, Third, Fourth, Sixth, Ninth, Tenth and Eleventh Circuits; and the U.S. District Courts for the District of Utah, the Eastern District of New York, the Eastern District of Michigan, the Northern District of California, the Southern District of New York and the Western District of Michigan.
Mr. Marriott received a B.A. magna cum laude from Brigham Young University in 1991 and a J.D. from New York University School of Law in 1994. After graduating, he served as law clerk to Hon. Eugene F. Lynch of the U.S. District Court for the Northern District of California and to Hon. Albert J. Engel of the U.S. Court of Appeals for the Sixth Circuit.
Mr. Marriott joined Cravath in 1996 and was elected a partner in 2002.
American Bar Association
American Bar Foundation
ICC National Arbitration Committee (U.S. Council for International Business)
International Academy of Trial Lawyers
International Bar Association
New York City Bar Association
New York State Bar Association
The American Lawyer
Benchmark Litigation
Top 100 Trial Lawyers in America (2024)
General Commercial Star - National (2024-2017)
Litigation Star - New York (2024-2017)
Future Star (2016, 2015)
Best Lawyers in America
Chambers USA
Euromoney Legal Media Group
Forbes
Intellectual Asset Management
Law360
Lawdragon
Leaders League Innovation - Technology & Intellectual Property Report
Leaders League Litigation & International Arbitration Report
The Legal 500 US
National Law Journal
Super Lawyers - New York
Who's Who Legal
Deals & Cases
April 29, 2024
On Monday, April 15, 2024, the U.S. Court of Appeals for the Second Circuit affirmed the U.S. District Court for the Southern District of New York’s granting of summary judgment in favor of Cravath client Mylan in a securities class action related to Mylan’s marketing, pricing and classification of EpiPen as well as alleged conduct concerning generic drug price fixing and market allocation.
Deals & Cases
January 29, 2024
On January 25, 2024, the U.S. District Court for the Southern District of New York entered judgments against appropriation artist Richard Prince and his co‑defendants Laurence Gagosian, Gagosian Gallery and Blum & Poe gallery.
Deals & Cases
September 11, 2023
Cravath represented Amgen, one of the world’s largest biopharmaceutical companies, in successfully defending against a Federal Trade Commission (“FTC”) challenge to Amgen’s pending $27.8 billion acquisition of Horizon Therapeutics (“Horizon”)—securing a consent order on September 1, 2023 that The Wall Street Journal described as “a rare instance” of the FTC “throwing in the towel on litigation.”
Deals & Cases
July 14, 2023
On July 13, 2023, a three judge panel for the U.S. Court of Appeals for the Third Circuit ruled in favor of Cravath clients Louis Dreyfus Company LLC (“LDC”) and Imperial Sugar Company (“Imperial Sugar”) and unanimously affirmed an earlier decision by the U.S. District Court for the District of Delaware denying U.S. Department of Justice’s (“DOJ”) request for an injunction to block LDC’s sale of the assets and business of Imperial Sugar to U.S. Sugar.
Deals & Cases
May 19, 2023
On May 11, 2023, the U.S. District Court for the Southern District of New York denied summary judgment to appropriation artist Richard Prince and his associated galleries in two copyright infringement cases brought by Cravath clients, the photographers Donald Graham and Eric McNatt, regarding works from Prince’s “New Portraits” series.
Accolades
June 27, 2024
On June 25, 2024, Cravath was honored for the second consecutive year with the Gold Award as “Best US Law Firm” at the 2024 Leaders League Alliance Summit: Law & Innovation, which was held in Miami. The award was accepted by partner David R. Marriott on the Firm’s behalf. Winners were selected by more than 80 jury members “through an extremely rigorous judging process” based on nominees’ “experience and market knowledge.” The information on which Cravath’s selection was based included its representation of global companies on large and complex M&A transactions, antitrust litigation and investigations matters, as well as its innovative use of new legal technology tools.
Accolades
June 13, 2024
The IAM Patent 1000 2024, which recognizes the firms and individuals “deemed outstanding in the pivotal area of patent law,” ranked Cravath in the top tier for New York across Litigation and Transactions. In addition, Cravath partners Keith R. Hummel, David J. Kappos, David R. Marriott, Sasha Rosenthal‑Larrea and Sharonmoyee Goswami were recognized for their “outstanding service” and representation of clients on litigation and transactional matters including Johnson & Johnson in its $16.6 billion acquisition of Abiomed; Abiomed in its victory before the U.S. Patent Trial and Appeal Board; and Truist Bank in patent infringement litigation brought by United Services Automobile Association.
Accolades
March 28, 2024
On March 26, 2024, Cravath partner David R. Marriott was named to Forbes’s 2024 list of “America’s Top 200 Lawyers.” The inaugural list recognized “the finest practitioners in the profession—lawyers with stellar track records in their specialties, those who have broken barriers to emerge as leaders in their fields, and attorneys most respected by peers and clients.” Dave’s accompanying profile highlighted his experience as a “courtroom heavyweight” and his representation of clients including AT&T, Avon Products, Bank of America, Bristol‑Myers Squibb, Colgate‑Palmolive and Delta Airlines. In particular, the publication noted Dave’s achievement of “setting precedent in antitrust and intellectual property law.”
Accolades
March 14, 2024
On March 13, 2024, Benchmark Litigation honored Cravath partner David R. Marriott as its “Trial Lawyer of the Year” at the publication’s twelfth annual U.S. Awards, which were held in New York City. The awards recognize “the country’s most distinguished litigators and their firms for their exemplary work over the past twelve months.”
Activities & Publications
February 08, 2024
On February 5, 2024, The Am Law Litigation Daily interviewed Cravath partner David R. Marriot in connection with his representation of photographers Donald Graham and Eric McNatt in winning judgments against appropriation artist Richard Prince and his co defendants Laurence Gagosian, Gagosian Gallery and Blum & Poe gallery, in a case at the intersection of art, technology and copyright law.
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2024 Cravath, Swaine & Moore LLP.